Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TE-8105 in overweight/obese participants without diabetes
NCT06471530Phase 2Completed
- Sponsor
- Immunwork
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of TE-8105 in obesity (7 cohorts), sponsored by Immunwork. Primary endpoints: Treatment-related Adverse Events at 155 days, Injection Site Reactions at 127 days and 8 more. Started Jul 2024; status: completed.
02
Drugs
TE-8105
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06471530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471530.